Severin Schwan, Roche CEO (Georgios Kefalas/Keystone via AP Images)

Covid-19 roundup: High­er an­ti­body counts seen in spaced-out vac­cine in­ter­vals — study; Roche CEO com­pares IP waiv­er to East Ger­man 'ex­per­i­ments'

Near the out­set of the UK’s vac­ci­na­tion cam­paign, the British gov­ern­ment out­lined plans to space out shots in larg­er in­ter­vals in or­der to get more peo­ple their first shot. Now, a study has come out say­ing the ap­proach can dri­ve a high­er an­ti­body re­sponse — at least in old­er pop­u­la­tions.

In a study with 175 peo­ple old­er than 80, the an­ti­body re­sponse was 3.5 times high­er in in­di­vid­u­als who re­ceived their sec­ond Pfiz­er/BioN­Tech shot 12 weeks af­ter their first, com­pared to those who fol­lowed the typ­i­cal three-week pe­ri­od. An­ti­body lev­els were mea­sured about two to three weeks af­ter the fol­low-up jabs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.